Real Questions and examcollection for RPFT exam

The particular majority of that will pass Registered Pulmonary Function Technologist tend not to trouble to send all of us their review nevertheless the write evaluation for your help associated with further actually assist others. We lastly, tune our RPFT cram simply by adding the latest, legitimate, and up upward to now queries in the RPFT examcollection plus removing obsolete queries. This makes all of us maintain the great copy associated with the complete pool associated with RPFT questions that assist to get complete marks in the part

Exam Code: RPFT Practice exam 2022 by Killexams.com team
Registered Pulmonary Function Technologist
Medical Technologist download
Killexams : Medical Technologist obtain - BingNews https://killexams.com/pass4sure/exam-detail/RPFT Search results Killexams : Medical Technologist obtain - BingNews https://killexams.com/pass4sure/exam-detail/RPFT https://killexams.com/exam_list/Medical Killexams : HPCL Technician Admit Card now available. Here's the link to download
Limited (HPCL), a Maharatna Central Public Sector Enterprise (CPSE), has released the HPCL Technician Admit Card 2022. The admit cards are available to obtain on its official website: hindustanpetroleum.com.

The computer based test (CBT) for recruitment of technicians will be conducted on August 8 this year (Sunday) and the admit cards have been made available for obtain from July 23. Candidates who clear the CBT, which will consist of general aptitude test and technical knowledge, will then have to undergo a medical examination for final selection. A mock test is also available on the

website for candidates.

In total, there are 186 vacancies for which HPCL has started the recruitment drive. The number includes vacancies for Operations Technician (94), Boiler Technician (18), Maintenance Technician(Mechanical) (14), Maintenance Technician(Electrical) (17), Maintenance Technician(Instrumentation) (9), Lab Analyst (6), and Jr Fire & Safety Inspector (18).


How to download

1)To obtain the admit card, visit the official website: hindustanpetroleum.com.
2) Go to Career section, and then click on Job Openings from the drop down menu
3) Scroll down and click on Recruitment of Technicians - Visakh Refinery option
4) Click on obtain Admit Card

You will need a few other details such as application number and date of birth to obtain the admit card.

Disclaimer: This content is authored by an external agency. The views expressed here are that of the respective authors/ entities and do not represent the views of Economic Times (ET). ET does not guarantee, vouch for or endorse any of its contents nor is responsible for them in any manner whatsoever. Please take all steps necessary to ascertain that any information and content provided is correct, updated and verified. ET hereby disclaims any and all warranties, express or implied, relating to the report and any content therein.

Mon, 25 Jul 2022 23:56:00 -0500 en text/html https://economictimes.indiatimes.com/news/new-updates/hpcl-technician-admit-card-now-available-heres-the-link-to-download/articleshow/93129018.cms
Killexams : Wearable Medical Device Market is expected to reach $11.4 Billion by 2027 – An exclusive market research report by Lucintel No result found, try new keyword!Trends and Forecast for the Global Wearable Medical Device Market Trends, opportunities and forecast in the wearable medical device market to 2027 by end use (healthcare & medical and remote patient ... Mon, 08 Aug 2022 10:58:00 -0500 https://finance.dailyherald.com/dailyherald/article/abnewswire-2022-8-8-wearable-medical-device-market-is-expected-to-reach-114-billion-by-2027-an-exclusive-market-research-report-by-lucintel Killexams : The Download: a hepatitis mystery, and chasing crypto

This is today's edition of The Download, our weekday newsletter that provides a daily dose of what's going on in the world of technology.

We’re starting to understand the mysterious surge of hepatitis in children

The news: Hundreds of young children around the world have developed severe cases of hepatitis with no obvious cause, leaving doctors baffled. But two new studies reveal the potential culprits: a combination of genetic factors, lockdowns, and at least two viruses.

Researchers believe the common adenovirus and another adeno-associated virus may be triggering the unexplained hepatitis in children with a gene that affects the way the immune system works. Lockdowns inadvertently seem to have played a part as adenoviruses surged as people began to mingle more after they were lifted. 

Why it matters: Although the World Health Organization reported 1,010 probable cases of the liver condition in 35 countries as of July 8, the true number of cases is likely to be higher. The situation is serious—around 5% of the children infected worldwide have needed liver transplants, and 22 have died.

What’s next?: Although researchers are still not confident which of the viruses is causing the condition, or which first infected a child, the small studies offer some much-needed insight into why the mysterious condition appears to be so widespread. They could also help to shed light on previous, similar cases that could have been trickling along for years. Read the full story.

—Jessica Hamzelou

How governments seize millions in cryptocurrency

There have been so many latest multimillion-dollar cryptocurrency thefts that it’s easy to lose track. Organized crime, bad cybersecurity, financially motivated spies, and colorful criminals of all kinds have made so many headlines that even huge heists can go mostly unnoticed by the public. 

But sometimes the government is able to get it back. Last week, the United States seized $500,000 in cryptocurrency from alleged North Korean hackers who got that money by extorting American medical organizations. That’s just a drop in the bucket considering the grand total: the IRS alone seized $3.5 billion in cryptocurrency in 2021.

Read our explanation on how the government tries to track, freeze, and seize stolen cryptocurrency—and what comes next.

—Patrick Howell O’Neill

The must-reads

I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.

1 Big Tech wants to kill the leap second 
The extra time has triggered internet outages and disturbances, they claim. (CNET)

2 QAnon ideology is thriving in the primaries
But savvy Republicans are avoiding explicitly outing themselves as believers. (NYT $)
+ Donald Trump refused to read lines condemning the Capitol rioters during a speech. (Reuters)
+ Pennsylvania's Democratic candidate’s social media game is exceptional. (The Guardian)

3 Venture capitalists are set to invest a record sum in crypto
Completely unfazed by the past six months, then. (Reuters)
+ Hacked crypto platforms are pleading with thieves to return part of their haul. (WSJ $)

4America’s pedestrians are in real danger
Roads built purely for vehicles are threatening the lives of humans trying to cross them. (Vox)
+ London is experimenting with traffic lights that put pedestrians first. (MIT Technology Review)

5 Facebook is even worse without news
Pulling the plug on articles leaves the platform looking like a content graveyard. (The Atlantic)
+ Its failure to curb hate speech is continuing to fuel violence in Ethiopia. (Insider)
+ Meta’s insistence in copying TikTok is getting a bit embarrassing. (Axios)
+ Instagram’s makeover hasn’t gone down well with users either. (TechCrunch)

6 Algorithms are warping our sense of style
Fueling a flat, generic taste designed to appeal to everyone, yet no one. (New Yorker $)
+ We’re contending with pricing algorithms designed to squeeze us for every penny, too. (NPR)

7 Roblox bent over backwards to appease Chinese censors
And even that didn’t stop it from having to shut down there after just a few months. (Motherboard)
+ Chinese gamers are using a Steam wallpaper app to get porn past the censors. (MIT Technology Review)

8 Inside the ongoing war over lending digital books
Physical libraries are being dragged into debates over copyright law. (WP $)

9 Tech entrepreneurs are selling shares in their lives
Because, why not? (New Yorker $)

10 Brace yourself for the return of the Glasshole 
Companies are desperate to sell us smart glasses—but do we actually want them? (The Verge)
+ Why Facebook is using Ray-Ban to stake a claim on our faces. (MIT Technology Review)

Quote of the day

“Where will it go next? Good luck out there, little bag.”

—Finbarr Taylor, whose suitcase went AWOL during a flight from California to Glasgow, mournfully follows his bag’s journey across the world courtesy of an Apple AirTag tracker, reports Bloomberg

The big story

Inside the machine that saved Moore’s Law

October 2021

In Wilton, Connecticut, Dutch company ASML is making the world’s most sophisticated machine for lithography—a crucial process used to create the transistors, wires, and other essential components of microchips. The team’s speed and accuracy is key to keeping up with Moore’s Law—the observation that the number of transistors crammed into a microchip doubles roughly every two years as components become ever smaller, making the chips cheaper and more powerful.

It took ASML $9 billion of R&D and 17 years of research to refine its industry-leading extreme ultraviolet (EUV) microchip machine. But the effort and time it took to make it happen raises some inevitable questions. How long will EUV be able to keep Moore’s Law going? And what will happen next? Read the full story.

Tue, 26 Jul 2022 00:05:00 -0500 en text/html https://www.technologyreview.com/2022/07/26/1056465/download-hepatitis-mystery-children-virus-government-crypto-seize-stolen/
Killexams : AIIMS Raipur invites applications for Advanced Diploma in Radiotherapy Technology, Pre-Hospital Trauma Technician courses, details

Raipur: All India Institute of Medical Sciences (AIIMS Raipur) has invited online applications for entrance examination for admission in Advanced Diploma in Radiotherapy Technology (ADRT) and Pre-Hospital Trauma Technician (PTT) courses - July 2022 session.

The candidates can apply till 20th August 2022. They can access the online application by clicking on the Google form link mentioned on the website www.aiimsraipur.edu.in. The application must be filled out carefully since after submission of the online application, a request for change in any information at any later stage will not be considered. While filling out the application form, the candidates should be ready with a valid email id, online payment detail of the required application fee, and an aadhar card.

Google link for the application form -

ADRT course - https://docs.google.com/forms/d/e/1FAIpQLSe03mu5NJU3s76-9vDGa4RwDx5ymLY-0L392YPJxSBUuWdaUA/viewform

PTT - https://docs.google.com/forms/d/e/1FAIpQLScec2ftaPHH8Dk8lqRxm6s-uiQ2L8qhEWpg5B1NRv2ngunESg/viewform

The candidates will have to pay the following application fee –

1. General/OBC Category - 1000/- + Transaction Charges as applicable.

2. SC/ST/EWS Category - 800/- + Transaction Charges as applicable.

3. PWBD Candidates are exempted from any Fee.

Without the payment of the application fee, the application will not be treated as complete. Candidates can pay the application fee through NEFT. The account details for fee payment are enclosed in the notice below. They must take a print of the receipt of the fee of application form for their records and future reference.

The admit card will be sent on the candidates' registered email ID. On 28th August 2022 (tentative), candidates applying for the ADRT course can obtain their admit cards. The entrance exam for the ADRT course is tentatively scheduled for 3rd September 2022. The exam will be pen-paper-based and conducted from 11:00 am to 12.30 pm. There will be multiple choice questions (MCQ) of 100 marks. The exam will be conducted at AIIMS Raipur. Selection to this course will be based on marks scored in the written examination only.

AIIMS has further notified that if large numbers of applications are received, nearby centers like Durg, Bhilai, and Bilaspur may be allotted. The final date of examination will be notified on admit card.

The candidates note that no entrance exam will be done for PTT courses. Selection will be based on aggregate percentage marks of Physics, Chemistry and Biology obtained in the 10+2 Examination of CBSE/State Board/any other recognized Board.

After the result of the Entrance Examination, candidates belonging to Scheduled Caste/Scheduled Tribe and Other Backward Classes should submit, along with other requisite documents, an attested copy of a certificate from the prescribed authorities. Reservation for EWS shall be according to the rules of the Government of India.

The guidelines for scanning photographs and signatures are enclosed in the notice below.

Overseas Citizens of India (001) registered under Section 7A of the Citizenship Act 1955 are also eligible to appear in PG courses, and all terms and conditions for Indian Nationals will apply to the candidates. The candidate will submit proof of Registration as OCI under Section 7A of the Citizenship Act 1955 to be eligible to appear for this test.

A total of 12 seats are available for both the above courses for July 2022 session. ADRT has 2 seats, and Pre-Hospital Trauma Technician Courses have 10 seats allotted. ADRT course is for 2 years with 1 year of internship, and Pre-Hospital Trauma Technician courses are for 1 year.

Qualification required –

Advanced Diploma in Radiotherapy Technology (ADRT) – Should have passed B.Sc. with the following subjects - Physics, Chemistry, and either Biology or Mathematics) with requisite percentage of marks (50% in aggregate for General, OBC, and EWS or 45% in aggregate in case of SC/ ST Categories). Those candidates who have completed or completed the qualifying examination on or before 31.08.2022 are eligible to apply. Still, such candidates must furnish proof of passing the qualifying examination at the time of counseling failing, and their candidature will be canceled.

Pre-Hospital Trauma Technician courses – Having Passed 10+2 with Science - Physics, Chemistry, and Biology Subjects with a minimum of 55% marks in the aggregates for General candidates and 50% marks for reserved category candidates.

Those candidates who have completed the 10+2 examination on or before 31st August 2022 are eligible to apply. Still, such candidates must furnish proof of passing the qualifying examination with the requisite percentage of marks and subjects at the time of counseling, failing which their candidature will be canceled.

Age limit –

Advance Diploma in Radiotherapy Technology (ADRT) - Between 20 and 25 years as on 31st August 2022. Age relaxation of 5 years for SC/ST and 3 years for OBC candidates as per Government norms.

Pre-Hospital Trauma Technician courses - Minimum 17 years and maximum 25 years as on 31st August 2022. However, the relaxation in age will be 05 (five) years for SC and ST candidates and 3 (Three) years for OBC candidates as per Government Rules /Instructions in this regard.

Joining dates for selected candidates –

1. ADRT course – 30th September 2022

2. PTT - The information related to date of counselling and joining will be intimated later.

The selected ADRT course candidates who fail to join by 30th September 2022 and fail to submit a written request for an extension till 30th September 2022 will not be eligible for admission. They will be considered uninterested, and the seat will be offered to the next candidate on the waiting list. The last date for admission to the course will be 31st October 2022.

Course fee and stipend –

Course

Fee for the entire course

Stipend

ADRT

Rs 5856

Rs 11000 per month for 2 years

Rs 18000 per month for internship

PTT

NIL

Rs 1500 per month

The candidates must bring all the original documents with one set of photocopies at the time of counselling.

To view the notice, click on https://medicaldialogues.in/pdf_upload/62eb9e91559bffinal-advertisment-of-adrt-and-ptt-july-2022-v2-182684.pdf.

Fri, 05 Aug 2022 18:00:00 -0500 en text/html https://medicaldialogues.in/news/education/aiims-raipur-invites-applications-for-advanced-diploma-in-radiotherapy-technology-pre-hospital-trauma-technician-courses-details-97109
Killexams : LENSAR Reports Second Quarter 2022 Financial Results and Provides Business Update

LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2022 and provided an update on operational initiatives.

"In June, we achieved a significant milestone in LENSAR's history, the Food and Drug Administration ("FDA")'s clearance of our ALLY Adaptive Cataract Treatment System. Interest in the ALLY System has been high since we initiated our pre-clearance marketing efforts and continues to increase as we near the commercial placement of the first system. We are navigating supply chain challenges and expect to have approximately 10 ALLY systems placed in the U.S. in 2022." said Nick Curtis, Chief Executive Officer of LENSAR. "Our results for the second quarter were impacted by several factors: strong U.S. procedure volumes were partially offset by softness in the rest of the world and product revenues declined as we completed placements of our last new LENSAR Laser Systems ("LLS"). We are extremely pleased with our continued progress and ability to navigate and successfully pivot around challenges outside of our company. We are proud of our ongoing accomplishments, including increasing U.S. femtosecond laser cataract procedure market share over the last few quarters, which we believe positions us well for our ALLY System launch this upcoming quarter. We view the initial launch and rollout of the ALLY System as the foundation for LENSAR's sustainable growth and success over the long-term."

Second Quarter 2022 Financial Results

Total revenue for the quarter ended June 30, 2022 was $8.0 million, an increase of $0.1 million, or 1%, compared to total revenue of $7.9 million for the quarter ended June 30, 2021. The increase was primarily attributable to increased procedure volume as compared to the second quarter of 2021, partially offset by a decline in revenue associated with lower LLS system sales in 2022 as we completed placement of the last new LLS systems as part of our operational transition to the ALLY System's commercial launch in the third quarter of 2022.

For the quarter ended June 30, 2022, approximately 99% of revenue was attributable to recurring sources compared to 90% for the quarter ended June 30, 2021. The following table provides information about procedure volume:

2022

2021

Q1

38,901

28,122

Q2

33,359

30,966

Total

72,260

59,088

Selling, general and administrative expenses for the quarter ended June 30, 2022 were $7.6 million, an increase of $2.1 million, or 37%, compared to $5.5 million for the quarter ended June 30, 2021. The increase was primarily attributable to increases in sales and marketing expenses of $0.9 million, which was primarily the result of increased trade show and travel activity, and an increase in professional fees of $0.7 million.

Research and development expenses were $3.8 million and $3.0 million for the quarters ended June 30, 2022 and 2021, respectively, an increase of $0.8 million or 28%. This increase was primarily due to the continued development of ALLY.

Net loss for the quarter ended June 30, 2022 was $6.8 million, or ($0.67) per share, compared to net loss of $4.4 million, or ($0.47) per share, for the quarter ended June 30, 2021. Included within operating expenses recorded for the quarters ended June 30, 2022 and 2021 are stock-based compensation expenses recorded for the quarters ended June 30, 2022 and 2021 of $1.6 million and $1.4 million, respectively, and ALLY System inventory costs of $1.0 million and $1.1 million, respectively.

Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA") for the quarter ended June 30, 2022 was ($5.9) million, compared with ($3.7) million for the quarter ended June 30, 2021. Adjusted EBITDA, which we calculate by adding back stock-based compensation expense to EBITDA, was ($4.3) million for the quarter ended June 30, 2022 and ($2.3) million for the quarter ended June 30, 2021. EBITDA and Adjusted EBITDA are non-GAAP financial measures, and a reconciliation of these measures to net loss is set forth below in this press release.

As of June 30, 2022, the Company had cash and cash equivalents of $25.2 million as compared to $31.6 million at December 31, 2021. Cash utilized in the quarter was $3.8 million, which was primarily attributable to ALLY System purchases and commercial readiness activities as well as a $1.2 million contingent consideration payment, which was contingent upon initial FDA clearance of the ALLY System. Based on its cash position and operational forecasts, the Company believes it has sufficient cash to fund operations into 2024.

Conference Call:

LENSAR management will host a conference call and live webcast to discuss the second quarter results and provide a business update today, August 8, 2022 at 8:30 a.m. ET.

To participate by telephone, please dial (888) 396-8049 (Domestic) or (416) 764-8646 (International). The conference ID number is 64265948. The live webcast can be accessed under "Events & Presentations" in the Investor Relations section of the company's website at https://ir.lensar.com. Please log in approximately 5-10 minutes prior to the call to register and to obtain and install any necessary software. The call and webcast replay will be available until August 22, 2022.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of visually significant astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its next-generation ALLY™ Adaptive Cataract Treatment System, the first platform to integrate proprietary imaging with a dual-pulse femtosecond laser in a compact system. ALLY is designed to transform cataract surgery by utilizing LENSAR's advanced technologies with the ability to perform the entire procedure in an operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR's proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company's commercialization of the ALLY™ Adaptive Cataract Treatment System and expectations about the Company's operational initiatives and business strategy, as well as the Company's cash and operational forecasts and ability to fund ongoing operating expenses. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "could," "expect," "should," "plan," "intend," "estimate," "target," "mission," "may," "will," "would," "should," "could," "target," "potential," "project," "predict," "contemplate," "potential," or the negative thereof and similar words and expressions.

Each of these forward-looking statements involves risks and uncertainties. actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's assets and business include, without limitation, its history of operating losses and ability to generate revenue; its ability to maintain, grow market acceptance of and enhance its LENSAR Laser and ALLY Systems; the impact of the COVID-19 pandemic and the Company's ability to grow revenues; the Company's ability to obtain any additional necessary clearances or approvals for the ALLY Adaptive Cataract Treatment System; the willingness of patients to pay the price difference for LENSAR products; its ability to grow a U.S. sales and marketing organization; its ability to meet its future capital needs; the impact of any material disruption to the supply or manufacture of ALLY Systems and its recurring revenue products; the ability of the Company to compete against competitors that have longer operating histories and more established products than the Company; the Company's ability to address numerous international business risks; and the other important factors that are disclosed under the heading "Risk Factors" contained in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, filed with the Securities and Exchange Commission ("SEC"), to be filed with the SEC, as such factors may be updated from time to time, including the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022 and in its other filings with the SEC, each accessible on the SEC's website at www.sec.gov and the Investor Relations section of the Company's website at https://ir.lensar.com. All forward-looking statements are expressly qualified in their entirety by such factors. Except as required by law, the Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. These forward-looking statements should not be relied upon as representing LENSAR's views as of any date subsequent to the date of this press release.

Non-GAAP Financial Measures

The Company prepares and analyzes operating and financial data and non-GAAP measures to assess the performance of its business, make strategic and offering decisions and build its financial projections. The key non-GAAP measures it uses are EBITDA and Adjusted EBITDA.

EBITDA is defined as net loss before interest expense, interest income, income tax expense, depreciation and amortization expenses. EBITDA is a non-GAAP financial measure. EBITDA is specifically disclosed because the Company believes that EBITDA provides meaningful supplemental information for investors regarding the performance of its business and facilitates a meaningful evaluation of actual results on a comparable basis with historical results. Adjusted EBITDA is also a non-GAAP financial measure. The Company believes Adjusted EBITDA, which excludes stock-based compensation expense, provides meaningful supplemental information for investors when evaluating its results and comparing it to peer companies as stock-based compensation expense is a significant non-cash charge due to the recapitalization of the Company. It uses these non-GAAP financial measures in order to have comparable financial results to analyze changes in its underlying business from quarter to quarter. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance and, therefore, any non-GAAP measures it use may not be directly comparable to similarly titled measures of other companies.

A reconciliation of EBITDA and Adjusted EBITDA to their most comparable GAAP financial measure are set forth below.

Three Months Ended
June 30,

Six Months Ended
June 30,

(Dollars in thousands)

2022

2021

2022

2021

Net loss

$

(6,759)

$

(4,362)

$

(13,433)

$

(9,544)

Less: Interest income

(39)

(13)

(48)

(31)

Add: Depreciation expense

569

342

1,110

670

Add: Amortization expense

287

309

596

622

EBITDA

(5,942)

(3,724)

(11,775)

(8,283)

Add: Stock-based compensation expense

1,637

1,430

3,244

3,750

Adjusted EBITDA

$

(4,305)

$

(2,294)

$

(8,531)

$

(4,533)

LENSAR, Inc.

STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

 

Three Months Ended
June 30,

Six Months Ended
June 30,

2022

2021

2022

2021

Revenue

Product

$

5,733

$

6,056

$

12,702

$

11,214

Lease

1,415

1,140

2,814

2,251

Service

890

726

1,862

1,500

Total revenue

8,038

7,922

17,378

14,965

Cost of revenue (exclusive of amortization)

Product

1,765

2,366

4,459

4,456

Lease

484

268

958

519

Service

897

830

2,377

1,638

Total cost of revenue

3,146

3,464

7,794

6,613

Operating expenses

Selling, general and administrative expenses

7,569

5,518

13,847

11,553

Research and development expenses

3,834

3,006

8,622

5,752

Amortization of intangible assets

287

309

596

622

Operating loss

(6,798)

(4,375)

(13,481)

(9,575)

Other income

Other income, net

39

13

48

31

Net loss

$

(6,759)

$

(4,362)

$

(13,433)

$

(9,544)

Net loss per share:

Basic and diluted

$

(0.67)

$

(0.47)

$

(1.34)

$

(1.03)

Weighted-average number of shares used in calculation of net loss per share:

Basic and diluted

10,073

9,296

10,020

9,242

LENSAR, Inc.

BALANCE SHEETS

(In thousands, except per share amounts)

 

June 30, 2022

December 31, 2021

Assets

Current assets:

Cash and cash equivalents

$

25,196

$

31,637

Accounts receivable, net of allowance of $25 and $47, respectively

2,760

4,638

Notes receivable, net of allowance of $181 and $61, respectively

164

350

Inventories

5,856

6,488

Prepaid and other current assets

1,230

1,700

Total current assets

35,206

44,813

Property and equipment, net

680

756

Equipment under lease, net

7,161

6,690

Notes and other receivables, long-term, net of allowance of $1 and $2, respectively

29

121

Intangible assets, net

12,674

10,870

Other assets

2,950

3,215

Total assets

$

58,700

$

66,465

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

$

4,191

$

2,694

Accrued liabilities

4,372

4,604

Contingent consideration

1,200

-

Deferred revenue

937

904

Operating lease liabilities

521

512

Total current liabilities

11,221

8,714

Long-term operating lease liabilities

2,540

2,803

Other long-term liabilities

37

69

Total liabilities

13,798

11,586

 

Stockholders' equity:

Preferred stock, par value $0.01 per share, 10,000 shares authorized at June 30, 2022 and December 31, 2021; no shares issued and outstanding at June 30, 2022 and December 31, 2021

-

-

Common stock, par value $0.01 per share, 150,000 shares authorized at June 30, 2022 and December 31, 2021; 11,021 and 10,990 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively

110

110

Additional paid-in capital

135,819

132,363

Accumulated deficit

(91,027)

(77,594)

Total stockholders' equity

44,902

54,879

Total liabilities and stockholders' equity

$

58,700

$

66,465

[ Back To TMCnet.com's Homepage ]

Sun, 07 Aug 2022 23:11:00 -0500 text/html https://www.tmcnet.com/usubmit/2022/08/08/9651829.htm
Killexams : Adopting Medical Cyber Physical Systems to Keep Up with an Increasing IoT World

Cookie List

A cookie is a small piece of data (text file) that a website – when visited by a user – asks your browser to store on your device in order to remember information about you, such as your language preference or login information. Those cookies are set by us and called first-party cookies. We also use third-party cookies – which are cookies from a domain different than the domain of the website you are visiting – for our advertising and marketing efforts. More specifically, we use cookies and other tracking technologies for the following purposes:

Strictly Necessary Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Functional Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Performance Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may Strengthen our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Social Media Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may Strengthen our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Targeting Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may Strengthen our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Tue, 02 Aug 2022 05:00:00 -0500 en text/html https://www.nextgov.com/sponsors/2022/08/adopting-medical-cyber-physical-systems-keep-increasing-iot-world/375227/
Killexams : CareerStep Launches Training Program to Meet Growing Demand for Medical Lab Assistants

Workforce training pioneer's flexible, skills-focused approach helps working learners earn credentials for in-demand allied health roles

BOSTON, Aug. 2, 2022 /PRNewswire/ -- Penn Foster-Carrus, whose jobtech platform is used by major employers nationwide to identify, recruit, and train workers for middle-skill careers, today announced the launch of a new training program for the fast-growing medical laboratory assistant role. Available through CareerStep, the new course prepares learners to sit for two industry-recognized and employer-preferred certification exams: the American Medical Technologists (AMT) Certified Medical Laboratory Assistant (CMLA) exam and the National Healthcare Association (NHA) Certified Phlebotomist Technician (CPT) exam.

Penn Foster (PRNewsfoto/Penn Foster)

The Bureau of Labor Statistics estimates that the demand for clinical lab-related skills will continue to accelerate in the next 8 years, as the volume of laboratory tests increases to meet both population growth and the development of new types of medical diagnostics. Penn Foster-Carrus' portfolio of healthcare training programs already includes in-demand fields like Phlebotomy, Medical Assistant, and Hemodialysis Technician; the addition of the Medical Laboratory Assistant program will enable more working learners to access affordable, job-aligned training programs that help them take the next step in their careers. Thanks to the unique design of the program's externship course, learners who complete and pass the certification exams will be fully certified for the role, with no other additional requirements needed.

"Middle-skill roles like medical lab assistant are critical to the country's labor market, and play a vital role in ensuring quality of care amidst a rapidly changing healthcare landscape," said Misty Frost, CEO of Penn Foster-Carrus. "This is not just about meeting the most immediate talent needs of hospital systems and healthcare providers, but also building a skilled workforce that is better-prepared to navigate a complex and dynamic labor market in the years to come."

Penn Foster and Carrus, which combined in 2021, now provide training in middle-skill fields like allied health, design, and skilled trades for more than 450,000 learners each year.

About Penn Foster
Penn Foster is bridging the gap between education and economic opportunity to build the workforce of tomorrow. We partner with employers to design and deliver digital and blended learning programs that attract, upskill, and retain workers in America's fastest-growing fields and professions. With more than 40,000 graduates each year, Penn Foster helps individuals discover pathways to opportunity through accredited diploma, certificate and degree programs that matter in the world of work. For more information, visit https://www.partners.pennfoster.edu.

About Carrus
Carrus delivers quality, trusted healthcare learning content, continuing education, and certification management to new learners, healthcare professionals, and institutions through an integrated technology platform that provides the most seamless healthcare learning experience possible. In 25+ years, Carrus—through its CareerStep and CareerCert divisions—has trained over 150,000 learners for new careers, partnered with more than 150 colleges and universities nationwide, and educated more than 100,000 healthcare professionals

Cision

View original content to obtain multimedia:https://www.prnewswire.com/news-releases/careerstep-launches-training-program-to-meet-growing-demand-for-medical-lab-assistants-301597177.html

SOURCE Penn Foster

Tue, 02 Aug 2022 01:00:00 -0500 en-US text/html https://finance.yahoo.com/news/careerstep-launches-training-program-meet-130000292.html
Killexams : Laser Technology Market worth $25.6 billion by 2027 - Exclusive Report by MarketsandMarkets

CHICAGO, Aug. 8, 2022 /PRNewswire/ -- Laser Technology Market size is estimated to be USD 16.7 billion in 2022 and is projected to reach USD 25.6 billion by 2027, at a CAGR of 8.9%, according to a new report by MarketsandMarkets. Increasing investments in R&D for developing laser-based weapons, increasing adoption of laser technology in optical communication, and growing preference of laser-based techniques for material processing across verticals such as automotive, semiconductor & electronics, and industrial are major factors driving the growth of the laser technology market. Additionally, growing adoption of smart manufacturing techniques is another key driver for the market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=795

Browse in-depth TOC on "Laser Technology Market"
191 - Tables
62 - Figures
242 - Pages

Solid laser to grow at the highest growth rate during the forecast period

Solid lasers and solid laser-based systems find applications across various verticals such as medical where they are used for spectroscopy and microscopy applications and automotive where they are used for metal processing applications. They are also used in optical transmission systems in the telecommunications industry and find applications in the defense industry owing to their ability to meet extreme power requirements.

System segment held the largest share and laser segment to register the highest growth during the forecast period

Laser engraving systems are extensively used for the marking of aircraft parts in the aerospace vertical. Additionally, laser engraving and marking systems are also used for development of smart cards and unique identification cards. The applications of lasers in the combat vehicles industry are increasing; lasers are mounted atop combat vehicles to track and detect enemy drones and support anti-drone capabilities. In the coming years, laser and laser systems are expected to provide support troops with additional security against artillery, rockets, drones, mortars, and cruise missiles.

Optical communication to demonstrate highest growth during the forecast period

Laser technology's low-payload weight feature makes it suitable for space telescopes, onboard satellites, and scientific space probe applications. In the coming years, laser technology is expected to gain importance in space applications, especially for transmitting large quantities of data between satellites. With increasing bandwidth requirements and a shift to 100G transceivers, the demand for lasers in optical communication is also growing. Laser technology devices play a vital role in broadband communications systems, which are used as high-speed transmitters in analog and digital fiber networks.

Medical vertical to register the highest growth during the forecast period

Laser technology are being extensively used in the medical vertical. The applications of laser technology in the medical sector include flow cytometry, cell sorting, microscopy, DNA sequencing, retinal scanning, plastic joining, metal welding, liquid processing, precision cleaning, stent cutting, cardiac pacemaker, and catheter laser welding systems. Optically pumped semiconductor lasers (OPSL) and diode lasers, resulting in a continuous solid UV laser enable the use of UV in clinical and research environments. Similarly, during the process of joining plastics in medical applications, a sealing system is required. Lasers offer reliable sealing in a single step, thereby increasing the adoption of laser technology in the medical domain. Lasers are also used extensively in therapeutics.

Request sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=795

The laser technology market in Asia Pacific held the largest share and the market in RoW is expected to grow significantly from 2022 to 2027

Asia Pacific is home to major automobile companies, such as Chery (China), Honda (Japan), Toyota Motor (Japan), Nissan (Japan), Kia Motors (South Korea), and Tata Motors (India). These companies have increased the adoption of laser technology for multiple operations such as welding, drilling, and cutting to Strengthen quality and precision and reduce turn-around time. Increasing accessibility to low-cost laser-based satellite broadband services and the development of laser-based innovative technologies are key factors driving the market growth in RoW. Additionally, increasing patients suffering from ophthalmic diseases in the region resulting in increasing demand for laser-based treatments is another factor driving the laser technology market. The growing use of electric vehicles in the Middle East is expected to boost the automotive industry, which, in turn, is expected to fuel the demand for laser processing systems in the region.

Major companies operating in the laser technology market include Coherent (US), IPG Photonics (US), Han's Laser (China), Jenoptik (Germany), TRUMPF (Germany), Gravotech (France), Lumentum (US), Novanta (US), Bystronic Lasers (Switzerland), and Lumibrid (France).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=795

Browse Adjacent Market: Semiconductor and Electronics Market Research Reports &Consulting

Related Reports:

Laser Interferometer Market by Interferometer Type (Michelson, Fabry-Perot, Fizeau, and Twyman-Green), Type, Application (Surface Topology, Engineering, and Science), End-User Industry, and Geography (2021-2026)

Silicon Photonics Market by Product (Transceivers, Switches), Application (Data Center & High-performance Computing, Telecommunication), Waveguide, Component, and Geography (2021-2027)

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/laser-technology-market.asp
Visit Our Web Site: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/laser-technologies.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

Mon, 08 Aug 2022 01:34:00 -0500 de text/html https://www.finanznachrichten.de/nachrichten-2022-08/56753239-laser-technology-market-worth-dollar-25-6-billion-by-2027-exclusive-report-by-marketsandmarkets-008.htm
Killexams : Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Three-Year Follow Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients receiving OvaStem® Procedure for Treating Primary Ovarian Insufficiency

PHOENIX, July 28, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced positive three-year follow up data for the Company’s OvaStem® pilot study. The data shows significant efficacy of the OvaStem® procedure for the treatment of medical refractory Primary Ovarian Insufficiency (POI) without any serious adverse effects and the successful birth of healthy babies.

OvaStem® is a patented outpatient clinic procedure that utilizes a patient’s own bone marrow aspirate for treatment of medical refractory POI. Below is a summary of the study’s three-year follow up data:

There were no safety related concerns at up to three years and the OvaStem® procedure resulted in an efficacy of 90% in the treated patients in terms of improvement in hormonal function and 70% in terms of delivery of healthy babies using their own eggs. Patients with POI usually only have a 5% to 10% chance of spontaneous pregnancy and must rely on donor eggs for conception via in vitro fertilization therapy. The company plans to submit a manuscript for publication in a peer reviewed journal and present the data at future fertility medicine conferences.

“The positive three-year data from our OvaStem® pilot study is very encouraging, and we are excited to engage with practitioners on further development and translation,” said Timothy Warbington, President and CEO of the company. “To our knowledge, this pilot study is one of the first to demonstrate the clinical efficacy of injecting bone marrow aspirate into the ovaries using a minimally invasive outpatient procedure, thereby repairing, remodeling and improving the function. We believe as we further develop the OvaStem® program there is great potential to help patients with POI to conceive and deliver babies using eggs from their own ovaries without having to use surrogacy or donor eggs. Despite all on-going research, there is no FDA approved treatment for POI.”

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of immunotherapy, urology, neurology, and orthopedics. For further information about the Company, please visit www.creativemedicaltechnology.com.

Forward Looking Statements

This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.

View original content to obtain multimedia: https://www.prnewswire.com/news-releases/creative-medical-technology-announces-positive-top-line-results-for-ovastem-pilot-study-301595212.html

SOURCE Creative Medical Technology Holdings, Inc.

Wed, 27 Jul 2022 23:31:00 -0500 en text/html https://apnews.com/press-release/pr-newswire/technology-health-medical-fc7cb2a744eee5f4dce0a610996ce873
Killexams : Medical Terminology Software Market latest Innovation and Upcoming Trends Analysis 2022-2030 | MDC Research

Market Data Centre

Medical Terminology Software Market 2022 - 2030 - Vendor Assessment (Company Profiles, Market Positioning, Strategies, latest Developments, Capabilities & Product Offerings / Mapping), Technology Assessment (Developments & Economic Impact), Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional FootPrint by MDC Research

Pune, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Medical Terminology Software Market by Vendor Assessment, Technology Assessment, Partner & Customer Ecosystem, type/solution, service, organization size, end-use verticals, and Region – Global Medical Terminology Software Market Forecast to 2030, published by Market Data Centre, The Medical Terminology Software Market is projected to grow at a solid pace during the forecast period. The presence of key players in the ecosystem has led to a compsetitive and diverse market. The advancement of digital transformation initiatives across multiple industries is expected to drive the worldwide Medical Terminology Software Market during the study period.

This COVID-19 analysis of the report includes COVID-19 IMPACT on the production and, demand, supply chain. This report provides a detailed historical analysis of the global Medical Terminology Software Market from 2017-to 2021 and provides extensive market forecasts from 2022-to 2030 by region/country and subsectors. The report covers the revenue, sales volume, price, historical growth, and future perspectives in the Medical Terminology Software Market.

Download Free sample PDF@ https://www.marketdatacentre.com/samplepdf/19746

                                                                                                                                         

Regional Analysis:

On the basis of Geography, the Global Medical Terminology Software Market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America is expected to hold a considerable share in the global Medical Terminology Software Market. Due to increasing investment for research and development process and adoption of solutions in the region whereas Asia-Pacific is expected to grow at a faster pace during the forecasted period.

The growing number of Medical Terminology Software Market players across regions is expected to drive market growth further. Moreover, increasing investments by prominent vendors in product capabilities and business expansion is expected to fuel the market during the study period. Many market players are finding lucrative opportunities in emerging economies like China and India, where the large populations are coupled with new innovations in numerous industries.

List of Companies Covered in the Medical Terminology Software Market Report:

  • BITAC

  • Carecom Ltd.

  • BT Clinical Computing

  • 3M

  • HiveWorx

  • B2i Healthcare

  • Wolters Kluwer

  • Apelon, Inc.

  • Intelligent Medical Objects, Inc.

  • Clinical Architecture, LLC

  • Among others.

Market Assessment

Technology Assessment

Vendor Assessment

Market Dynamics

Key Innovations

Product Breadth and Capabilities

Trends and Challenges

Adoption Trends and Challenges

Technology Architecture

Drivers and Restrains

Deployment Trends

Competitive Differentiation

Regional and Industry Dynamics

Industry Applications

Price/Performance Analysis

Regulations and Compliance

Latest Upgrardation

Strategy and Vision


In deep ToC includes

233 – Tables

45  – Figures

300 – Pages

Get Table Of Content of the Report @ https://www.marketdatacentre.com/toc/19746

                                                                                                                                  

Table of Contents                                                                           

1.      INTRODUCTION
1.1.   Market Definition
1.2.   Market Segmentation
1.3.   Geographic Scope
1.4.   Years Considered: Historical Years – 2017 & 2020; Base Year – 2021; Forecast Years – 2022 to 2030
1.5.   Currency Used
2.      RESEARCH METHODOLOGY
2.1.   Research Framework
2.2.   Data Collection Technique
2.3.   Data Sources
2.3.1.      Secondary Sources
2.3.2.      Primary Sources
2.4.   Market Estimation Methodology
2.4.1.      Bottom-Up Approach
2.4.2.      Top-Down Approach
2.5.   Data Validation and Triangulation
2.5.1.      Market Forecast Model
2.5.2.      Limitations/Assumptions of the Study
3.      ABSTRACT OF THE STUDY
4.      MARKET DYNAMICS ASSESSMENT
4.1.   Overview
4.2.   Drivers
4.3.   Barriers/Challenges
4.4.   Opportunities
5.      VALUE CHAIN ANALYSIS
6.      PRICING ANALYSIS
7.      SUPPLY CHAIN ANALYSIS
8.      MARKET SIZING AND FORECASTING
8.1.   Global - Medical Terminology Software Market Analysis & Forecast, By Region
8.2.   Global - Medical Terminology Software Market Analysis & Forecast, By Segment
8.2.1.      North America Medical Terminology Software Market, By Segment
8.2.2.      North America Medical Terminology Software Market, By Country
8.2.2.1.            US
8.2.2.2.            Canada
8.2.3.      Europe Medical Terminology Software Market, By Segment
8.2.4.      Europe Medical Terminology Software Market, By Country
8.2.4.1.            Germany
8.2.4.2.            UK
8.2.4.3.            France
8.2.4.4.            Rest of Europe (ROE)
8.2.5.      Asia Pacific Medical Terminology Software Market, By Segment
8.2.6.      Asia Pacific Medical Terminology Software Market, By Country
8.2.6.1.            China
8.2.6.2.            Japan
8.2.6.3.            India
8.2.6.4.            Rest of Asia Pacific (RoAPAC)
8.2.7.      Rest of the World (ROW) Medical Terminology Software Market, By Segment
8.2.8.      Rest of the World (ROW) Medical Terminology Software Market, By Country
8.2.8.1.            Latin America
8.2.8.2.            Middle East & Africa

ToC can be modified as per clients' business requirements*

Read Overview of the Report @ https://www.marketdatacentre.com/medical-terminology-software-market-19746

                                                                

Key Questions Answered in This Report:

  • How does our product and services portfolio compare to leading competitors?

  • What are the key developments in customer demand given the changing economy?

  • What are the new pricing and consumption models in the marketplace and how should we align our portfolio?

  • What are the key decision drivers for services buyers?

  • How can we accelerate our bidding process?

  • What is the potential of the Medical Terminology Software Market?

  • What is the impact of COVID-19 on the global Medical Terminology Software Market?

  • What are the top strategies that companies adopting in Medical Terminology Software Market?

  • What are the challenges faced by SME’s and prominent vendors in Medical Terminology Software Market?

  • Which region has the highest investments in Medical Terminology Software Market?

  • What are the latest research and activities in Medical Terminology Software Market?

  • Who are the prominent players in Medical Terminology Software Market?

  • What is the potential of the Medical Terminology Software Market?

Vendor Assessment

Vendor assessment includes a deep analysis of how vendors are addressing  the demand in the Medical Terminology Software Market. The MDC CompetetiveScape model was used to assess qualitative and quantitative insights in this assessment. MDC's CompetitiveScape is a structured method for identifying key players and outlining their strengths, relevant characteristics, and outreach strategy. MDC's CompetitiveScape allows organizations to analyze the environmental factors that influence their business, set goals, and identify new marketing strategies. MDC Research analysts conduct a thorough investigation of vendors' solutions, services, programs, marketing, organization size, geographic focus, type of organization and strategies.

Technology Assessment

Technology dramatically impacts business productivity, growth and efficiency.Technologies can help companies develop competitive advantages, but choosing them can be one of the most demanding decisions for businesses. Technology assessment helps organizations to understand their current situation with respect to technology and offer a roadmap where they might want to go and scale their business. A well-defined process to assess and select technology solutions can help organizations reduce risk, achieve objectives, identify the problem, and solve it in the right way. Technology assessment can help businesses identify which technologies to invest in, meet industry standards, compete against competitors.

Business Ecosystem Analysis

Advancements in technology and digitalization have changed the way companies do business; the concept of a business ecosystem helps businesses understand how to thrive in this changing environment. Business ecosystems provide organizations with opportunities to integrate technology in their daily business operations and Strengthen research and business competency. The business ecosystem includes a network of interlinked companies that compete  and cooperate to increase sales, Strengthen profitability, and succeed in their markets. An ecosystem analysis is a business network analysis that includes the relationships amongst suppliers, distributors, and end-users in delivering a product or service.

Get a sample Copy of the Report @ https://www.marketdatacentre.com/sample/19746

Regions and Countries Covered

North America (US, Canada), Europe (Germany, UK, France, Spain, Italy, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, Rest of Asia-Pacific), and Rest of the World (RoW).

Report Coverage

Medical Terminology Software Market Dynamics, Covid-19 Impact on the Medical Terminology Software Market, Vendor Profiles, Vendor Assessment, Strategies, Technology Assessment, Product Mapping, Industry Outlook, Economic Analysis, Segmental Analysis, Medical Terminology Software Market Sizing, Analysis Tables.

Buy Exclusive Report @ https://www.marketdatacentre.com/checkout/19746

                                                                                                                          

About MDC:

Market Data Centre (Subsidiary of Yellow Bricks Global Services Private Limited)

Market Data Centre offers complete solutions for market research reports in miscellaneous businesses.These decisions making process depend on wider and systematic extremely important information created through extensive study as well as the most latest trends going on in the industry.The company also attempts to offer much better customer-friendly services and appropriate business information to achieve our clients’ ideas.

CONTACT: Market Data Centre (Subsidiary of Yellow Bricks Global Services Private Limited) Office 808, Amar Business Park, S.No. 105, Baner Road, Pune 411045, India Email: sales@marketdatacentre.com Phone: +1-916-848-6986 (US) Website: https://www.marketdatacentre.com/
Fri, 05 Aug 2022 01:34:00 -0500 en-US text/html https://finance.yahoo.com/news/medical-terminology-software-market-recent-133400350.html
RPFT exam dump and training guide direct download
Training Exams List